Company Overview of Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. researches, develops, manufactures, markets, and sells prescription pharmaceutical products. Its products include Vivelle-Dot and Estradot, which are transdermal estrogen patches; CombiPatch and Estalis, which are combination estrogen/progestogen patches; Stavzor, a delayed release valproic acid softgel; Pexeva, a paroxetine mesylate; Lithobid, a lithium carbonate; Brisdelle, a paroxetine capsule for the treatment of vasomotor symptoms associated with menopause; and Daytrana, a methylphenidate transdermal system. It also manufactures Daytrana, a prescription central nervous system stimulant patch system for the treatment of ADHD in the age group of 6 to 17 years o...
11960 SW 144th Street
Miami, FL 33186
Founded in 1987
Key Executives for Noven Pharmaceuticals, Inc.
Chief Executive Officer and President
Vice President of Operations
Chief Scientific Officer and Vice President
Chief Medical Officer and Executive Vice President of Product Development
Compensation as of Fiscal Year 2014.
Noven Pharmaceuticals, Inc. Key Developments
Noven Appoints Krista Roberts as Vice President of Operations
Jun 23 14
Noven Pharmaceuticals, Inc. announced the appointment of Krista Roberts as the company's new Vice President of Operations. In this role, Roberts will be responsible for all Noven manufacturing and related operations, reporting to Jeffrey Eisenberg, Noven's President and Chief Executive Officer. Roberts succeeds Richard Gilbert, who retired in April 2014. Roberts has over 15 years' experience in the pharmaceutical and medical device industries. Prior to joining Noven, she held various positions within Baxter International, serving most recently as Plant Manager of Baxter's 600+ person manufacturing facility in Cleveland, Mississippi. Her prior roles at Baxter included Director of Manufacturing, Manufacturing Manager, Manufacturing Superintendent, Department Engineer, and Manufacturing Supervisor.
Noven Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-26-2014 11:30 AM
Jun 17 14
Noven Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-26-2014 11:30 AM. Venue: San Diego Convention Center, San Diego, California, United States.
Noven Pharmaceuticals, Inc. Announces Settlement of Lidoderm(R) Patent Litigation with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc
Apr 16 14
Noven Pharmaceuticals, Inc. announced that it has entered into an agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related to Noven's lidocaine topical patch 5% product. An Abbreviated New Drug Application for Noven's product is currently pending at the U.S. Food and Drug Administration (FDA). If approved, Noven's product would be a generic version of Endo's Lidoderm(R). The agreement allows Noven to launch its generic Lidoderm(R) product on or after March 1, 2015, if the product is approved by the FDA. The agreement provides for an earlier launch under certain circumstances. Pursuant to the agreement, the litigation on this matter, currently pending in U.S. District Court for the District of Delaware, will be dismissed. Other terms of the settlement were not disclosed. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|